Analyzing Boston Scientific (NYSE:BSX) and Biomerica (NASDAQ:BMRA)
by Mitch Edgeman · The Markets DailyBiomerica (NASDAQ:BMRA – Get Free Report) and Boston Scientific (NYSE:BSX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Earnings & Valuation
This table compares Biomerica and Boston Scientific”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomerica | $4.45 million | 1.52 | -$3.78 million | ($1.27) | -1.73 |
| Boston Scientific | $20.07 billion | 3.08 | $2.90 billion | $2.47 | 17.25 |
Boston Scientific has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
22.3% of Biomerica shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 18.0% of Biomerica shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for Biomerica and Boston Scientific, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
| Boston Scientific | 2 | 5 | 23 | 0 | 2.70 |
Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 310.21%. Boston Scientific has a consensus target price of $67.96, suggesting a potential upside of 59.50%. Given Biomerica’s higher possible upside, research analysts plainly believe Biomerica is more favorable than Boston Scientific.
Profitability
This table compares Biomerica and Boston Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biomerica | -84.79% | -97.19% | -61.57% |
| Boston Scientific | 17.50% | 19.28% | 10.89% |
Risk & Volatility
Biomerica has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Summary
Boston Scientific beats Biomerica on 12 of the 14 factors compared between the two stocks.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.